OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 901–1,000 of 1,030
An Integrated Computational Model of the Bone Microenvironment in Bone-Metastatic Prostate Cancer
Araujo, A., Cook, L. M., Lynch, C. C., & Basanta, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2652 · Cited by 91
“pOCs and osteoclasts pOCs are derived from myeloid precursors and, in response to RANKL, undergo cellular fusion to generate mature osteoclasts (13).”
BackgroundKey roles of the OPG–RANK–RANKL system in bone oncology
Baud’huin, M., Duplomb, L., Velasco, C. R., Fortun, Y., Heymann, D., & Padrines, M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.2.221 · Cited by 87
Low, E., Zoellner, H. F., Kharbanda, O. P., & Darendeliler, M. A. (2005) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2004.03.038 · Cited by 99
Long-lived immature dendritic cells mediated by TRANCE-RANK interaction
Cremer, I., Dieu-Nosjean, M.-C., Maréchal, S., Dezutter-Dambuyant, C., Goddard, S., Adams, D., Winter, N., Menetrier-Caux, C., Sautès-Fridman, C., Fridman, W. H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0312 · Cited by 85
Megakaryocyte-mediated inhibition of osteoclast development
Kacena, M. A., Nelson, T., Clough, M. E., Lee, S., Lorenzo, J. A., Gundberg, C. M., & Horowitz, M. C. (2006) · Bone · doi:10.1016/j.bone.2006.05.004 · Cited by 92
Mouri, Y., Yano, M., Shinzawa, M., Shimo, Y., Hirota, F., Nishikawa, Y., Nii, T., Kiyonari, H., Abe, T., Uehara, H., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003533 · Cited by 94
“We speculate that the actions of the RANK and CD40 signals have significant redundancy at critical point(s) for mTEC differentiation, because the defect of thymic organization in Rankl/Cd40-DKO was much more profound than that in Rankl-KO, despite the apparently normal thymic architecture of Cd40-KO.”
InfluentialSelf-citationQiu, W., Hu, Y., Andersen, T. E., Jafari, A., Li, N., Chen, W., & Kassem, M. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052001 · Cited by 89
Nagata, N., Kitaura, H., Yoshida, N., & Nakayama, K. (2003) · Bone · doi:10.1016/s8756-3282(03)00213-8 · Cited by 89
“OPGL-deficient mice showed severe osteopetrosis and completely lacked osteoclasts [11].”
BackgroundProtective role of n-3 lipids and soy protein in osteoporosis
Fernandes, G., Lawrence, R. A., & Sun, D. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00060-7 · Cited by 94
Darnay, B. G., & Aggarwal, B. B. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i2 · Cited by 93
Houben, A., Kostanova‐Poliakova, D., Weißenböck, M., Graf, J., Teufel, S., von der Mark, K., & Hartmann, C. (2016) · Development · doi:10.1242/dev.137489 · Cited by 87
Physiological Functions of Osteoblast Lineage and T Cell–Derived RANKL in Bone Homeostasis
Fumoto, T., Takeshita, S., Ito, M., & Ikeda, K. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2096 · Cited by 75
“These data indicated that the expression of Cre, and therefore that of Rankl, in osteoblast lineage cells can be controlled through Dox administration.”
BackgroundInfluentialEndogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesis
Rahman, M. M., Bhattacharya, A., Banu, J., Kang, J. X., & Fernandes, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00649.x · Cited by 88
Inflammation in periodontal tissues in response to mechanical forces.
Yamaguchi, M., & Kasai, K. (2005) · PubMed · Cited by 99
New roles of osteoblasts involved in osteoclast differentiation
Yamashita, T., Takahashi, N., & Udagawa, N. (2012) · World Journal of Orthopedics · doi:10.5312/wjo.v3.i11.175 · Cited by 97
Heath, D. J., Vanderkerken, K., Cheng, X., Gallagher, O., Prideaux, M., Murali, R., & Croucher, P. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1287 · Cited by 82
“RANKL, a tumor necrosis factor (TNF) family member, binds to its receptor RANK on osteoclast precursors to stimulate osteoclastogenesis and bone resorption (5, 6).”
BackgroundSomayaji, S. N., Ritchie, S., Sahraei, M., Marriott, I., & Hudson, M. C. (2008) · Infection and Immunity · doi:10.1128/iai.00228-08 · Cited by 83
“RANK-L is one such key molecule that stimulates differentiation in osteoclasts and is an inducing agent involved in bone destruction (24, 25, 46, 49, 57).”
BackgroundGenome-wide principles of gene regulation by the vitamin D receptor and its activating ligand
Pike, J. W. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.012 · Cited by 89
“This factor was identified in 1999 as RANKL, a membrane-bound TNF-like molecule that not only induced the formation of osteoclasts, but stimulated their activation and survival as well (Burgess et al., 1999; Kong et al., 1999; Lacey et al., 1998).”
Westenfeld, R., Schlieper, G., Woltje, M., Gawlik, A., Brandenburg, V., Rutkowski, P., Floege, J., Jahnen-Dechent, W., & Ketteler, M. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr214 · Cited by 84
“As shown by the bone phenotypes of knockout mice, the OPG–RANKL–RANK system represents the master switch in osteoclast differentiation [34–36].”
BackgroundPathogenesis of Hemophilic Arthropathy
Hoots, W. K. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.11.026 · Cited by 83
Zheng, Y., Zhou, H., Brennan, K., Blair, J. M., Modzelewski, J. R. K., Seibel, M. J., & Dunstan, C. R. (2007) · Bone · doi:10.1016/j.bone.2006.09.016 · Cited by 82
“By sequestering RANKL, OPG inhibits osteoclastogenesis and thus bone resorption in vitro and in vivo [18–22].”
BackgroundSelf-citationEffects of receptor activator of NFκB (RANK) signaling blockade on fracture healing.
Flick, L. M., Weaver, J. M., Ulrich‐Vinther, M., Abuzzahab, F., Zhang, X., Dougall, W. C., Anderson, D., O'Keefe, R. J., & Schwarz, E. M. (2003) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(03)00011-1 · Cited by 82
1α,25 Dihydroxyvitamin D3 Rapidly Regulates the Mouse Osteoprotegerin Gene Through Dual Pathways
Kondo, T., Kitazawa, R., Maeda, S., & Kitazawa, S. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040604 · Cited by 99
Kitazawa, R., & Kitazawa, S. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0205 · Cited by 89
“In view of the fact that RANKL expression is limited among stromal/ osteoblastic cells and a small subset of T-lymphocytes (9, 28), we speculate that methylation of the RANKL gene promoter region is associated with the tissue-specific expression of the gene.”
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
Issa, M. E., Takhsha, F. S., Chirumamilla, C. S., Perez-Novo, C. A., Berghe, W. V., & Cuendet, M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0319-5 · Cited by 84
“Binding of RANKL to RANK activates different signal transduction pathways in osteoclasts, including mitogen-activated protein kinase (MEK), extracellular signal-regulated kinase 1/2 (ERK1/2), phosphatidylinositol 3-kinase, (PI3K), Akt kinase, mammalian target of rapamycin (mTOR), and transforming growth factor β (TGF-…”
BackgroundMeng, Y., Zhou, W., Jin, L., Liu, L.-B., Chang, K., Mei, J., Li, H., Wang, J., Li, D., & Li, M. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.505 · Cited by 87
New aspects of IFN‐α/β signalling in immunity, oncogenesis and bone metabolism
Takaoka, A., & Taniguchi, T. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01455.x · Cited by 81
Kuprash, D. V., Alimzhanov, M. B., Tumanov, A. V., Anderson, A. O., Pfeffer, K., & Nedospasov, S. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6575 · Cited by 87
“Additionally, opgl mice (34) also completely lack LNs.”
BackgroundYamagishi, T., Otsuka, E., & Hagiwara, H. (2001) · Endocrinology · doi:10.1210/en.142.8.3632 · Cited by 88
The Role of Osteoclast-Associated Receptor in Osteoimmunology
Nemeth, K., Schoppet, M., Al‐Fakhri, N., Helas, S., Jessberger, R., Hofbauer, L. C., & Goettsch, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002483 · Cited by 85
“In contrast, mice with a disrupted Tnfsf11 gene encoding RANKL develop osteopetrosis due to the lack of osteoclasts and display defects in lymphocyte development and lymph node organogenesis (17).”
BackgroundT‐lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow
Di Rosa, F. (2009) · Immunology & Cell Biology · doi:10.1038/icb.2008.84 · Cited by 80
Silva, T. A., Batista, A. C., Mendonça, E. F., Leles, C. R., Fukada, S. Y., & Cunha, F. Q. (2007) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2007.06.009 · Cited by 93
A Novel Mutation in the Nfkb2 Gene Generates an NF-κB2 “Super Repressor”
Tucker, E. J., O’Donnell, K., Fuchsberger, M., Hilton, A. A., Metcalf, D., Greig, K. T., Sims, N. A., Quinn, J. M. W., Alexander, W. S., Hilton, D. J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7514 · Cited by 86
Kabe, Y., Yamada, J., Uga, H., Yamaguchi, Y., Wada, T., & Handa, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.512-522.2005 · Cited by 91
“ODF knockout mice exhibit typical osteoporosis with total occlusion of bone marrow space within endosteal bone (21) and also fail to develop mammary glands (10).”
BackgroundParacrine regulation of osteoclast formation and activity: milestones in discovery.
Martin, T. (2004) · PubMed · Cited by 92
Osteoclasts—Key Players in Skeletal Health and Disease
Novack, D. V., & Mbalaviele, G. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0011-2015 · Cited by 86
Tolba, M. F., El-Serafi, A. T., & Omar, H. A. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.03.021 · Cited by 81
“The later mediator is secreted by a subset of osteoblasts and it acts as a decoy receptor for RANKL hindering its binding to its cognate receptor RANK and hence neutralizing its activity (Kong et al., 1999).”
BackgroundAsanuma, Y., Chung, C. P., Oeser, A. M., Solus, J. F., Avalos, I., Gebretsadik, T. S., Shintani, A., Raggi, P., Sokka, T., Pincus, T., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.04.049 · Cited by 84
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.
Gravallese, E. M., Galson, D. L., Goldring, S. R., & Auron, P. E. (2001) · Arthritis Research · doi:10.1186/ar134 · Cited by 87
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Mihara, M., Ohsugi, Y., & Kishimoto (2011) · Open Access Rheumatology: Research and Reviews · doi:10.2147/oarrr.s17118 · Cited by 75
Advanced oral vaccine delivery strategies for improving the immunity
Zhang, Y., Li, M., Du, G., Chen, X., & Sun, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113928 · Cited by 81
Ma, T., Miyanishi, K., Suen, A. W., Epstein, N. J., Tomita, T., Smith, R. L., & Goodman, S. B. (2004) · Cytokine · doi:10.1016/j.cyto.2004.02.001 · Cited by 83
Kook, S., Jang, Y., & Lee, J. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23205 · Cited by 80
“Orthodontic force can stimulate PLF to secrete various neuropeptides which induce the migration of leucocytes into the capillaries present in and around PDL [Krishnan and Davidovitch, 2006].”
BackgroundSphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis
Ishii, M., & Kikuta, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.06.002 · Cited by 80
Fukushima, H., Jimi, E., Okamoto, F., Motokawa, W., & Okabe, K. (2005) · Bone · doi:10.1016/j.bone.2004.09.011 · Cited by 86
Targeting Interleukin-6 in Rheumatoid Arthritis
Yusof, M. Y. M., & Emery, P. (2013) · Drugs · doi:10.1007/s40265-013-0018-2 · Cited by 87
“interaction between receptor activator of nuclear factor (NF)jB (RANK) and its ligand (RANKL) [61, 62].”
BackgroundInfluentialCowardin, C. A., Ahern, P. P., Kung, V. L., Hibberd, M. C., Cheng, J., Guruge, J. L., Sundaresan, V. M., Head, R. D., Barile, D., Mills, D. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821770116 · Cited by 79
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
Ming, J., Cronin, S. J. F., & Penninger, J. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01283 · Cited by 84
“In the thymus, the RANKL/RANK pathway is critical for CD80 AIRE medullary thymic epithelial cell (mTEC) maturation involved in central immune tolerance (9, 49, 55).”
BackgroundSelf-citationMarini, H. R., Minutoli, L., Polito, F., Bitto, A., Altavilla, D., Atteritano, M., Gaudio, A., Mazzaferro, S., Frisina, A., Frisina, N., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080201 · Cited by 82
Yip, K. H. M., Zheng, M., Steer, J. H., Giardina, T. M., Han, R., Lo, S. Z. Y., Bakker, A. J., Cassady, A. I., Joyce, D. A., & Xu, J. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050324 · Cited by 81
TNFα-dependent development of lymphoid tissue in the absence of RORγt+ lymphoid tissue inducer cells
Furtado, G. C., Pacer, M. E., Bongers, G., Bénézech, C., He, Z., Chen, L., Berin, M. C., Kollias, G. A., Caamaño, J., & Lira, S. A. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.79 · Cited by 81
Osteopetrosis and Its Relevance for the Discovery of New Functions Associated with the Skeleton
Coudert, A. E., de Vernejoul, M. C., Muraca, M., & Fattore, A. D. (2015) · International Journal of Endocrinology · doi:10.1155/2015/372156 · Cited by 90
Hyaluronan Increases RANKL Expression in Bone Marrow Stromal Cells Through CD44
Cao, J. J., Singleton, P. A., Majumdar, S., Boudignon, B., Burghardt, A., Kurimoto, P., Wronski, T. J., Bourguignon, L. Y., & Halloran, B. P. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041014 · Cited by 75
Effects of Denosumab Treatment and Discontinuation on Human Growth Plates
Wang, H. D., Boyce, A. M., Tsai, J. Y., Gafni, R. I., Farley, F. A., Kasa-Vubu, J. Z., Molinolo, A., & Collins, M. T. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3081 · Cited by 79
Matsumoto, M., Sudo, T., Maruyama, M., Osada, H., & Tsujimoto, M. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02231-6 · Cited by 79
Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment
Sezer, O. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0003 · Cited by 82
Terashima, A., & Takayanagi, H. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0417-1 · Cited by 81
“Interestingly, both Rankl−/− and Rank−/− mice lack the lymph nodes (LNs) and display a defect in Peyer’s patches (PPs) and cryptopatches (CPs), demonstrating the critical role for RANK activation during the early stages of development of lymphoid tissue inducer cells in the peripheral lymphoid organs [16, 17].”
BackgroundNew and emerging concepts in the use of denosumab for the treatment of osteoporosis
Lewiecki, E. M. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18805759 · Cited by 75
Selective Runx2-II deficiency leads to low-turnover osteopenia in adult mice
Xiao, Z., Awad, H. A., Liu, S., Mahlios, J., Zhang, S., Guilak, F., Mayo, M. S., & Quarles, L. D. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.04.028 · Cited by 82
“…osteoblastic factors RANK (receptor activator of NF-κB) ligand, which promotes osteoclast formation, and osteoprotegerin (OPG), which is an antagonist that competes with RANK as a decoy receptor for RANK-L and thus attenuates osteoclast differentiation (Kong and Penninger, 2000;Kong et al., 1999).”
BackgroundIchikawa, H., Nair, M. S., Takada, Y., Sheeja, D. B. A., Kumar, M. A. S., Oommen, O. V., & Aggarwal, B. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0916 · Cited by 87
IL-4 Inhibits Bone-Resorbing Activity of Mature Osteoclasts by Affecting NF-κB and Ca2+ Signaling
Mangashetti, L. S., Khapli, S. M., & Wani, M. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.917 · Cited by 95
“Transgenic and gene knockout studies in mice established the absolute dependency of osteoclast differentiation and activation on the expression of RANKL and RANK (7, 8).”
BackgroundCampagnuolo, G., Bolon, B., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10369 · Cited by 78
Environmental arginine controls multinuclear giant cell metabolism and formation
Brunner, J. S., Vulliard, L., Hofmann, M., Kieler, M., Lercher, A., Vogel, A., Russier, M., Brüggenthies, J. B., Kerndl, M., Saferding, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14285-1 · Cited by 79
Emerging Functions of RANKL in Lymphoid Tissues
Mueller, C. G., & Hess, E. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00261 · Cited by 84
Inactivation of Tgfbr2 in Osterix-Cre expressing dental mesenchyme disrupts molar root formation
Wang, Y., Cox, M. K., Coricor, G., MacDougall, M. J., & Serra, R. A. (2013) · Developmental Biology · doi:10.1016/j.ydbio.2013.08.003 · Cited by 81
“RANKL is also required for tooth eruption (Kong et al., 1999).”
BackgroundRamírez, A., Faupel, J., Goebel, I., Stiller, A., Beyer, S., Stöckle, C., Hasan, C., Bode, U., Kornak, U., & Kubisch, C. (2004) · Human Mutation · doi:10.1002/humu.20028 · Cited by 82
“The genetic heterogeneity of ARO is illustrated by several spontaneous mouse mutants (e.g., gl/gl, oc/oc) [Grynpas, 1993; Marks et al., 1985] and by mouse models developed by gene targeting (e.g., c-Fos, c-Src, Opgl) [Kong et al., 1999; Soriano et al., 1991; Wang et al., 1992] that are osteopetrotic.”
BackgroundInflammation-Induced Bone Loss: Can it Be Prevented?
Romas, E., & Gillespie, M. T. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.07.004 · Cited by 87
Sparks, A. B., Peterson, S. N., Bell, C., Loftus, B., Hocking, L. J., Cahill, D. P., Frassica, F. J., Streeten, E. A., Levine, M. A., Fraser, C. M., et al. (2001) · Calcified Tissue International · doi:10.1007/s002230001211 · Cited by 83
“Subsequent work showed that the RANK-RANKL signaling pathway was essential for osteoclastogenesis as well as lymph node organogenesis [23–29].”
BackgroundFuruya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77
“RANKLdeficient mice and RANK-deficient mice exhibited severe osteopetrosis with lack of osteoclasts (12, 13).”
BackgroundResultSelf-citationHenriksen, K., Flores, C., Thomsen, J. S., Brüel, A.-M., Thudium, C. S., Neutzsky-Wulff, A. V., Langenbach, G. E. J., Sims, N., Askmyr, M., Martin, T. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027482 · Cited by 77
Role of TGF-β in breast cancer bone metastases
Chiechi, A., Waning, D. L., Stayrook, K. R., Buijs, J. T., Guise, T. A., & Mohammad, K. S. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.410a4003 · Cited by 77
“RANKL/RANK knockout mice develop severe osteopetrosis due to total lack of osteoclast [83,84].”
BackgroundThe role of microRNA in periodontal tissue: A review of the literature
Irwandi, R. A., & Vacharaksa, A. (2016) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2016.08.014 · Cited by 80
Fan, X., Zhao, Z., Gu, Y., Han, J., Ye, K., & Zhang, Y. (2021) · eLife · doi:10.7554/elife.64872 · Cited by 79
Hong, M. H., Williams, H., Jin, C. H., & Pike, J. W. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.911 · Cited by 76
Rattanakul, C., Lenbury, Y., Krishnamara, N., & Wollkind, D. J. (2003) · Biosystems · doi:10.1016/s0303-2647(03)00040-6 · Cited by 77
Rhee, E., Lee, W., Kim, S.-Y., Kim, B. J., Sung, K., Kim, B.-S., Kang, J.-H., Oh, K.-W., Eun-Sook, O. H., Baek, K., et al. (2005) · Clinical Science · doi:10.1042/cs20040255 · Cited by 79
Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells
Kanamaru, F., Iwai, H., Ikeda, T., Nakajima, A., Ishikawa, I., & Azuma, M. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.05.010 · Cited by 90
TAK1-dependent Activation of AP-1 and c-Jun N-terminal Kinase by Receptor Activator of NF-κB
Lee, S.-W., Han, S.-I., Kim, H.-H., & Lee, Z.-H. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.4.371 · Cited by 77
“Therefore, there is evidence for the essential role of the RANK-RANKL signal in osteoclastogenesis, lymphocyte development, and lymph node organogenesis (Dougall et ., 1999, Kong et al., 1999).”
BackgroundTeng, Y.-T. A., Mahamed, D., & Singh, B. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3453-3461.2005 · Cited by 77
“Genetic mutations of RANKL and RANK demonstrate similar phenotypes in OC development with severe osteopetrosis, suggesting that they are essential for osteoclastogenesis during bone remodeling (26, 28, 50).”
Do immune cells lead the way in subchondral bone disturbance in osteoarthritis?
Weber, A., Chan, P. M., & Wen, C. (2017) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2017.12.004 · Cited by 78
Molecular Regulation of Bone Metastasis Pathogenesis
Wu, M., Li, C.-J., Yiang, G., Cheng, Y., Tsai, A. P., Hou, Y.-T., Ho, Y.-C., Hou, M., & Chu, P. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489184 · Cited by 79
Tauro, M., & Lynch, C. C. (2018) · Cancers · doi:10.3390/cancers10060185 · Cited by 82
“RANKL, a member of the tumor necrosis factor (TNF) family, is a trimeric cell-surface ligand that is essential for promoting the fusion of myeloid cells into multinucleated osteoclasts [85].”
BackgroundMano, M., Arakawa, T., Mano, H., Nakagawa, M., Kaneda, T., Kaneko, H., Yamada, T., Miyata, K., KIYOMURA, H., Kumegawa, M., et al. (2000) · Calcified Tissue International · doi:10.1007/s00223001102 · Cited by 77
“Recently, ODF/OPGL/TRANCE/RANKL was identified as a mediator of the above-mentioned PGE 2-promoting stimulation of osteoclast formation [12, 13].”
BackgroundBSP and RANKL Induce Osteoclastogenesis and Bone Resorption Synergistically
Valverde, P., Tu, Q., & Chen, J. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050511 · Cited by 82
Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76
RANKL/RANK: from bone loss to the prevention of breast cancer
Sigl, V., Jones, L. P., & Penninger, J. M. (2016) · Open Biology · doi:10.1098/rsob.160230 · Cited by 76
“RANK and RANKL are also essential for lymph node organogenesis, because Rank and Rankl mice completely lack lymph nodes [2,3].”
BackgroundSelf-citationWang, B., Feng, C., Liu, Y., Mi, F., & Dong, J. (2022) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2022.07.002 · Cited by 79
“RANKL induces precursors into mature osteoclasts by binding to RANK on the surface of osteoclast precursor cells [121].”
BackgroundMolecular Actions of 1,25-Dihydroxyvitamin D3 on Genes Involved in Calcium Homeostasis
Pike, J. W., Zella, L. A., Meyer, M. B., Fretz, J. A., & Kim, S. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.07s207 · Cited by 73
“Future studies will be needed to determine whether these enhancers mediate the actions of these cytokine or other known regulators of RANKL expression in T cells and other cell types where RANKL is known to be expressed.((18))”
BackgroundRegulatory Mechanisms of RANKL Presentation to Osteoclast Precursors
Honma, M., Ikebuchi, Y., Kariya, Y., & Suzuki, H. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0189-0 · Cited by 80
Role of RANKL in bone diseases
Anandarajah, A. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.10.007 · Cited by 84
Inhibition of Bone Metastasis from Breast Carcinoma by Rosmarinic Acid
Xu, Y., Jiang, Z., Ji, G., & Liu, J. (2010) · Planta Medica · doi:10.1055/s-0029-1240893 · Cited by 80
Pangrazio, A., Cassani, B., Guerrini, M. M., Crockett, J. C., Marrella, V., Zammataro, L., Strina, D., Schulz, A., Schlack, C., Kornak, U., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.559 · Cited by 79
The Effect of Vascular Endothelial Growth Factor on Osteoclastogenesis in Rheumatoid Arthritis
Kim, H., Kim, K., Kim, B., Cho, M., & Lee, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124909 · Cited by 76
Benslimane-Ahmim, Z., Heymann, D., Dizier, B., Lokajczyk, A., Brion, R., Laurendeau, I., Bièche, I., Smadja, D. M., Galy–Fauroux, I., Colliec‐Jouault, S., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04207.x · Cited by 78
Voskaridou, E., Anagnostopoulos, A., Konstantopoulos, K., Stoupa, E., Spyropoulou, E., Kiamouris, C., & Terpos, E. (2006) · PubMed · Cited by 76
Molecular Basis for the Unique Specificity of TRAF6
Chung, J. Y., Lu, M., Yin, Q., Lin, S., & Wu, H. (2007) · Springer eBooks · doi:10.1007/978-0-387-70630-6_10 · Cited by 84
Kitaura, H., Nagata, N., Fujimura, Y., Hotokezaka, H., Yoshida, N., & Nakayama, K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4732 · Cited by 72
“This notion is supported by the finding that the targeted disruption of the gene encoding RANKL in mice develops severe osteopetrosis with the complete absence of TRAP-positive cells in bone tissues (11).”
BackgroundResultNovel osteoclast signaling mechanisms
Shinohara, M., & Takayanagi, H. (2007) · Current Osteoporosis Reports · doi:10.1007/s11914-007-0005-1 · Cited by 72
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Skoumal, M., Kolarz, G., Haberhauer, G., Woloszczuk, W., Hawa, G., & Klingler, A. (2005) · Rheumatology International · doi:10.1007/s00296-004-0579-1 · Cited by 66
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.